Kiniksa, Kite in Mavrilimumab Collaboration

By Chris Wack

Kite, a Gilead Sciences Inc. (GILD) company, and Kiniksa Pharmaceuticals Ltd. (KNSA) said Wednesday that they will be collaborating in a Phase 2, multicenter study of mavrilimumab, a investigational fully human monoclonal antibody, in combination with Yescarta axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma.

The companies said the study aims to determine the effect of mavrilimumab on the safety of Yescarta. Kite will conduct the study.

Mavrilimumab hasn't been approved by the U.S. Food and Drug Administration or any regulatory authority for any uses. Efficacy and safety of the antibody haven't been established.

Kiniksa shares were up 7% to $13.84 premarket, while Gilead shares were up 1%.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

December 11, 2019 09:23 ET (14:23 GMT)

Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Apr 2024 to May 2024